In tests on cells and mice, RIG-1, the molecule in question, a drug-like compound, was able to induce genes that controlled infections in a range of viruses, including, West Nile, dengue, hepatitis C, Ebola and influenza, among others. This is the first compound shown to trigger innate immunity therapeutically, from a molecule present in every human cell, according to researchers.
When the cellular protein RIG-1 detects viral RNA, it triggers an innate immune response that expresses other antiviral genes and cells, which act together to prevent the virus from taking hold. Should further testing in animal models produce positive results, RIG-1 could be manipulated to produce the equivalent of a broad-spectrum antibiotic for viruses.
More articles on infection control:
Kaiser Permanente bans interior building antimicrobials from its hospitals to curb antibiotic resistance, chemical exposure
Saline water vs. soap: Which is better for cleaning wounds?
WHO publishes list of emerging diseases likely to cause major outbreaks
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
